LENZ

LENZ Therapeutics, Inc.

$5.50

-$0.20 (-3.45%)Today

-$0.09 (-1.61%)After Hours

Key Statistics

Market cap175.27M

Price-Earnings ratio-1.61

Dividend yield—

Average volume1.09M

High today$5.86

Low today$5.34

Open price$5.85

Volume1.2M

52 Week high$50.40

52 Week low$5.23

Company Profile

Description

LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.

Sector

Healthcare

Industry

Biotechnology

CEO

Mr. Evert B. Schimmelpennink

Website

lenz-tx.com

Company Profile

Description

Sector

Healthcare

Industry

Biotechnology

CEO

Mr. Evert B. Schimmelpennink

Website

lenz-tx.com

LENZ

Key Statistics

Company Profile

Company Profile

Recent News

LENZ Therapeutics (LENZ) Stock Fair Value Moves Lower As Analysts Reset Growth Assumptions

Sir Speedy Annual Convention Recognizes Top-Performing Franchises Across the Nation

Dennis Van Allemeersch Joins Jobiqo's Advisory Board

Potomac Financial Group Partners with Concurrent to Launch Independent RIA

LENZ Therapeutics Announces Launch of New Telehealth Prescribing Option to Accelerate Patient Access to VIZZ® for the Treatment of Presbyopia

Goldman’s RIA Custody Making Gains on Name Recognition, UHNW Focus

Eight microcap stocks of companies expected to grow sales by triple digits through 2028

Fuchs Endothelial Corneal Dystrophy Market Forecast Highlights Significant Growth During the Forecast Period (2026-2036), Owing to the Expanding Treatment Landscape and Increasing Patient Pool | DelveInsight

Recent News

Company Profile

Recent News

LENZ Therapeutics (LENZ) Stock Fair Value Moves Lower As Analysts Reset Growth Assumptions

Sir Speedy Annual Convention Recognizes Top-Performing Franchises Across the Nation

Dennis Van Allemeersch Joins Jobiqo's Advisory Board

Potomac Financial Group Partners with Concurrent to Launch Independent RIA

LENZ Therapeutics Announces Launch of New Telehealth Prescribing Option to Accelerate Patient Access to VIZZ® for the Treatment of Presbyopia

Goldman’s RIA Custody Making Gains on Name Recognition, UHNW Focus

Eight microcap stocks of companies expected to grow sales by triple digits through 2028

Fuchs Endothelial Corneal Dystrophy Market Forecast Highlights Significant Growth During the Forecast Period (2026-2036), Owing to the Expanding Treatment Landscape and Increasing Patient Pool | DelveInsight